The findings showed that compared with chemotherapy alone, both PD-1 + Chemo and PD-L1 + Chemo had statistically meaningful differences in terms of OS and PFS, which suggests that PD-1 + Chemo improves outcomes in ES-SCLC. The gene discussed is PDCD1; the disease is small cell lung carcinoma.